Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer

Creative Commons License

Bayoglu I. V., Yildiz I., Varol U., Cokmert S., Kucukzeybek Y., Alacacioglu A., ...More

JOURNAL OF BUON, vol.20, pp.460-467, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20
  • Publication Date: 2015
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.460-467
  • Eskisehir Osmangazi University Affiliated: No


Purpose: Currently, there are several oxaliplatin combination regimens for first-line therapy of metastatic colorectal cancer (mCRC). In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (rnFOLFOX6) or capecitabine/oxaliplatin (XELOX).